Clinical and regulatory intelligence for Still's Disease with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Assets: 1

Relevant assets

MAS825 →

Relevant companies

Novartis →

Recent signals(1)

ClinicalJuly 11, 2026

Novartis initiates Phase II trial of MAS825 for Still's Disease

Novartis is conducting Phase II trial to assess the efficacy and safety of MAS825 in patients with Still's disease.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Rheumatology →

Still's Disease →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.